Position in SVTR
Snapshot 2026-10-20- Startup SignalsRankedof 2,259↓20
- Life SciencesRankedof 238↓2
About
Silvia Bio is a University of Sheffield spinout founded in 2025 that combines a bioinformatics platform, proprietary cell-profiling assays and precision-engineered media additives to identify and fix bottlenecks limiting yield and quality in CHO-based biologic drug manufacturing.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Founders / core team
Investors
Funding history
- 2026-10-15Seed$4M
Investors · Northern Gritstone、Parkwalk Northern Universities Venture Fund、UK Innovation & Science Seed Fund、Wren Capital
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Silvia Bio
Silvia Bio is a University of Sheffield spinout founded in 2025 that combines a bioinformatics platform, proprietary cell-profiling assays and precision-engineered media additives to identify and fix bottlenecks limiting yield and quality in CHO-based biologic drug manufacturing.
Seed · $4M · 2026-10
$4M
United States
BusinessLatest roundTotal raisedDate- Pepper Bio
Pepper Bio, founded in 2018 in Massachusetts, USA, analyzes multi-layered biological data—including DNA, RNA, proteomic, and phosphoproteomic data—to discover novel drug candidates.
Seed · $7M · 2023-12
$7M - Fieldstone Bio
Fieldstone Bio, founded in 2023 in the United States, develops AI-based biosensor technology that uses programmed microorganisms to detect environmental hazards such as toxins and explosives, and employs hyperspectral imaging and AI to map the distribution of these compounds.
Seed · $5M · 2025-05
$5M - Dash Bio
Dash Bio is a bioanalysis company founded in 2024 in Boston that applies automation and AI to accelerate drug development.
Undisclosed · $11M · 2025-07
$11M
China
BusinessLatest roundTotal raisedDateEurope
BusinessLatest roundTotal raisedDate- Arsenale Bioyards
Arsenale Bioyards, founded in 2022 in Milan, Italy, combines advanced bioreactors with AI-driven software to optimize fermentation processes in biomanufacturing, aiming to reduce precision fermentation costs by up to 90% and accelerate the adoption of sustainable alternatives.
Undisclosed · $10M · 2025-03
$10M - OutSee
OutSee, founded in 2022 in Cambridge, UK, uses AI to analyze individual genomes and predict disease biological mechanisms, helping drug developers identify new therapeutic targets. Its core platform, Nomaly, is a proprietary AI engine developed by founder and CEO Dr. Julian Gough that employs hypothesis-free modeling to predict disease and phenotypes directly from individual genomes, enabling insights from smaller cohorts or previously intractable datasets.
Seed · $2M · 2025-06
$2M - ScienceMachine
ScienceMachine, founded in 2024 in London, UK, builds AI bioinformatics agents to automate experiments and data analysis.
Pre-Seed · $4M · 2025-07
$4M
Other / unspecified
BusinessLatest roundTotal raisedDate- Reliant AI
Reliant AI, founded in 2023 and headquartered in Montreal, Canada and Berlin, Germany, uses generative AI to help biopharmaceutical companies organize and analyze large volumes of complex data for use cases such as clinical trials and scientific publications.
Seed · $11M · 2024-08
$11M - Promise Bio
Promise Bio, founded in 2022 in Tel Aviv, has developed a cloud-based AI platform that analyzes protein modifications in blood samples to predict treatment response in patients with autoimmune diseases.
Seed · $8M · 2024-12
$8M - NiaHealth
NiaHealth, founded in 2025 in Edmonton, Canada, offers a home biomarker testing subscription service combined with AI-driven insights and one-on-one clinical consultations to help users detect and prevent chronic diseases.
Pre-Seed · $2M · 2025-04
$2M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Y Combinator
38 Life Sciences deals in the last 24 months · 26 at a nearby stage · 1 in United Kingdom
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 3 at a nearby stage · 3 in United Kingdom
Request intro →GV
14 Life Sciences deals in the last 24 months · 3 at a nearby stage · 3 in United Kingdom
Request intro →Alumni Ventures
12 Life Sciences deals in the last 24 months · 8 at a nearby stage · 1 in United Kingdom
Request intro →Accel
12 Life Sciences deals in the last 24 months · 8 at a nearby stage · 2 in United Kingdom
Request intro →Catalio Capital Management
8 Life Sciences deals in the last 24 months · 2 at a nearby stage · 1 in United Kingdom
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.